+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Type (Molecular Biomarkers, Cellular Biomarkers), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 125 Pages
  • July 2024
  • Region: Global
  • Grand View Research
  • ID: 5681738
Description Jump to:
The global biomarker testing services market size is expected to reach USD 1.05 billion by 2030, registering a CAGR of 8.46% from 2024 to 2030, according to a new report. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights

  • The biomarker assay development & validation segment by service was expected to hold the largest share of 45.61% in 2023. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
  • Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 45.7% in 2023, owing to the rising investment in R&D by these companies
  • North America held the largest share of 46.2% in 2023, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definition
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Purchased Database
1.3.3. Internal database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Detail
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
1.9.1. Objective - 1:
1.9.2. Objective - 2:
1.9.3. Objective - 3:
1.9.4. Objective - 4:
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Service Outlook
2.2.2. Type Outlook
2.2.3. End-Use Outlook
2.3. Competitive Insights
Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Demand for Biomarker Testing for Cancer Detection
3.2.1.2. Increasing R&D Activities
3.2.1.3. Growing Burden of Chronic and Infectious Diseases Supporting Demand for Biomarker Testing
3.2.2. Market Restraint Analysis
3.2.2.1. High Capital Investments and Lengthy Timelines for Biomarker Development
3.3. Biomarker Testing Services Market: Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.4. COVID-19 Impact Analysis
Chapter 4. Biomarker Testing Services Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Biomarker Testing Service Market Movement Analysis
4.3. Global Biomarker Testing Service Market Size & Trend Analysis, by services, 2018 to 2030 (USD Million)
4.4. Biomarker Assay Development & Validation
4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
4.5. Flow Cytometry
4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 5. Biomarker Testing Services Market: Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Biomarker Testing Services Market Movement Analysis
5.3. Global Biomarker Testing Services Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Molecular Biomarkers
5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
5.5. Cellular Biomarkers
5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 6. Biomarker Testing Services Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Biomarker Testing Services Market Movement Analysis
6.3. Global Biomarker Testing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical and Biotechnology Companies
6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5. Research Institutes
6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.6. CROs
6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 7. Biomarker Testing Services Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Scenario
7.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.3. Japan
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.8. Indonesia
7.6.8.1. Key Country Dynamics
7.6.8.2. Competitive Scenario
7.6.8.3. Regulatory Scenario
7.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.9. Malaysia
7.6.9.1. Key Country Dynamics
7.6.9.2. Competitive Scenario
7.6.9.3. Regulatory Scenario
7.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.10. Singapore
7.6.10.1. Key Country Dynamics
7.6.10.2. Competitive Scenario
7.6.10.3. Regulatory Scenario
7.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6.11. Taiwan
7.6.11.1. Key Country Dynamics
7.6.11.2. Competitive Scenario
7.6.11.3. Regulatory Scenario
7.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.7.4. Colombia
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8.6. Israel
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Scenario
7.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Service Heat Map Analysis (a comparative analysis of the players together)
8.3. Company Profiles
8.3.1. Bio Agilytix Labs
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Service Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Eurofins Scientific
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Service Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. SGS SA.
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Service Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Charles River Laboratories
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Service Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. LabCorp
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Service Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Thermo Fisher Scientific Inc. (PPD, Inc.)
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Service Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. ICON Plc
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Service Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. IQVIA
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Service Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Syneos Health
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Service Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Intertek Group Plc
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Service Benchmarking
8.3.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List oList of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 4. Global Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 5. Global Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 6. Global Biomarker Testing Services, by Region, 2018 - 2030 (USD Million)
Table 7. North America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
Table 8. North America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 9. North America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 10. North America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 11. U.S. Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 12. U.S. Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 13. U.S. Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 14. Canada Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 15. Canada Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 16. Canada Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 17. Mexico Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 18. Mexico Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 19. Mexico Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 20. Europe Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
Table 21. Europe Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 22. Europe Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 23. Europe Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 24. Germany Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 25. Germany Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 26. Germany Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 27. UK Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 28. UK Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 29. UK Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 30. France Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 31. France Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 32. France Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 33. Italy Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 34. Italy Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 35. Italy Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 36. Spain Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 37. Spain Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 38. Spain Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 39. Denmark Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 40. Denmark Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 41. Denmark Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 42. Sweden Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 43. Sweden Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 44. Sweden Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 45. Norway Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 46. Norway Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 47. Norway Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 48. Asia Pacific Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
Table 49. Asia Pacific Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 50. Asia Pacific Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 51. Asia Pacific Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 52. China Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 53. China Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 54. China Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 55. Japan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 56. Japan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 57. Japan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 58. India Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 59. India Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 60. India Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 61. South Korea Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 62. South Korea Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 63. South Korea Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 64. Australia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 65. Australia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 66. Australia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 67. Thailand Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 68. Thailand Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 69. Thailand Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 70. Indonesia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 71. Indonesia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 72. Indonesia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 73. Malaysia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 74. Malaysia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 75. Malaysia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 76. Singapore Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 77. Singapore Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 78. Singapore Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 79. Taiwan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 80. Taiwan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 81. Taiwan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 82. Latin America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
Table 83. Latin America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 84. Latin America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 85. Latin America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 86. Brazil Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 87. Brazil Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 88. Brazil Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 89. Argentina Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 90. Argentina Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 91. Argentina Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 92. Middle East & Africa Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
Table 93. Middle East & Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 94. Middle East & Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 95. Middle East & Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 96. South Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 97. South Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 98. South Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 99. Saudi Arabia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 100. Saudi Arabia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 101. Saudi Arabia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 102. UAE Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 103. UAE Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 104. UAE Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 105. Kuwait Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 106. Kuwait Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 107. Kuwait Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
Table 108. Israel Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
Table 109. Israel Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
Table 110. Israel Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Biomarker Testing Services, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 Porter’s Five Forces Analysis
Fig. 10 PESTEL Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 Global Biomarker Testing Services, for Biomarker Assay Development & Validation, 2018 - 2030 (USD Million)
Fig. 13 Global Biomarker Testing Services, for Flow Cytometry, 2018 - 2030 (USD Million)
Fig. 14 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
Fig. 15 Global Biomarker Testing Services, for Molecular Biomarkers, 2018 - 2030 (USD Million)
Fig. 16 Global Biomarker Testing Services, for Research Institutes, 2018 - 2030 (USD Million)
Fig. 17 Global Biomarker Testing Services, for CROs, 2018 - 2030 (USD Million)
Fig. 18 Regional Outlook, 2023 & 2030
Fig. 19 North America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 20 U.S. Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 21 Canada Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 22 Mexico Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 23 Europe Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 24 Germany Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 25 UK Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 26 France Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 27 Italy Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 28 Spain Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 29 Denmark Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 30 Sweden Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 31 Norway Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 32 Asia Pacific Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 33 Japan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 34 China Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 35 India Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 36 Australia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 South Korea Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 38 Thailand Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 39 Indonesia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 40 Malaysia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 41 Singapore Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 42 Taiwan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 43 Latin America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 44 Brazil Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 45 Argentina Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 Middle East and Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 47 South Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 48 Saudi Arabia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 49 UAE Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 50 Kuwait Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 51 Israel Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Bio Agilytix Labs
  • Eurofins Scientific
  • SGS SA.
  • Charles River Laboratories
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc. (PPD, Inc.)
  • ICON Plc
  • IQVIA
  • Syneos Health
  • Intertek Group Plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages125
PublishedJuly 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 602.8 Million
Forecasted Market Value ( USD ) by 2030 $ 1056.5 Million
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Biomarker Testing Services Market by Services, Techonology, Disease Area, Application, End-User - Global Forecast 2025-2030 - Product Image

Biomarker Testing Services Market by Services, Techonology, Disease Area, Application, End-User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Cardiac Biomarkers Testing Global Market Report 2024 - Product Image

Cardiac Biomarkers Testing Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From
2024 Global Forecast for Pd-L1 Biomarker Testing Platform Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Pd-L1 Biomarker Testing Platform Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.